All Stories

  1. Newly Designed Expedited Allocation Pathways Cannot be Expected to Rely On Data that Does Not Currently Exist
  2. Allocation out of Sequence, as Currently Practiced in the United States, Cannot be Ethically Justified
  3. Association Between Primary Language and Evaluation Completion Among Kidney Transplant Candidates
  4. Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection
  5. Expanding Our Understanding of Genetic Variations That Impact Post-Transplant Outcomes
  6. Center behavior and location, and its impact on transplant disparities
  7. Dynamic Risk Prediction of Graft Failure after Deceased Donor Kidney Transplant
  8. Development of potent HLA-A02:01-restricted peptide-based cytotoxic T-cells against SARS-CoV-2 infections in patients awaiting a kidney transplant
  9. Correction to: Can a Rising Transplant Tide LYFT All Boats?
  10. Evaluation of the stability of organ procurement organization performance metrics
  11. Out-of-Sequence Placement of Deceased Donor Kidneys Is Exacerbating Inequities in the United States
  12. Consent to Receive Offers for Kidneys From Donors With Hepatitis C Among Pediatric Kidney Transplant Candidates in the United States
  13. The Associations Between Individual-Versus Neighborhood-level Incomes and Kidney Transplant Outcomes
  14. Changes in characteristics of recovered United States deceased donor kidneys lead to large changes in Kidney Donor Risk Index-to-Kidney Donor Profile Index scaling over time
  15. Socioeconomic Disparities in Out-of-Sequence Placement of Deceased Donor Kidneys in the US
  16. Acceptance of High Kidney Donor Profile Index Kidneys Among Consented Candidates
  17. Rationale and Design of the International Prospective Study of CKD of Uncertain Etiology in Agricultural Communities
  18. Association between out-of-sequence allocation and deceased donor kidney nonuse across organ procurement organizations
  19. Association of the initial implementation of continuous distribution allocation policy with outcomes for lung transplant candidates by blood type
  20. Decreasing efficiency in deceased donor kidney offer notifications under the new distance-based kidney allocation system
  21. Six‐ Versus Four‐Hour Iohexol Clearance for Glomerular Filtration Rate Measurement in Living Kidney Donor Candidates
  22. Underrecognition of deceased donor kidney out-of-sequence allocation due to increasing use of free-text coding
  23. Long-Term Exposure to Uranium and Arsenic in Community Drinking Water and CKD Risk Among California Women
  24. Association of Collapsing Glomerulopathy with Donor Apolipoprotein L1 Risk Variants in Kidney Allografts from Black Donors
  25. Community Water Trihalomethanes and Chronic Kidney Disease
  26. Can a Rising Transplant Tide LYFT All Boats?
  27. Erratum to “Patient and Provider Attitudes Toward Patient-Facing Kidney Organ Offer Reporting” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1122-1130]
  28. Association between private insurance and living donor kidney transplant: Affordable Care Act as a natural experiment
  29. Financial Toxicity in ESKD
  30. Environmental exposure assessment in the international prospective study of Chronic Kidney Disease of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) research consortium: Design and protocol development
  31. Risk Factors for Disease Progression for Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN)
  32. Variation of eGFR Wait Time Modifications for Black Kidney Transplant Candidates in the United States
  33. Association of organ procurement organization volume with Centers for Medicare and Medicaid Services performance evaluations
  34. Authors’ reply to letter regarding “Association of organ procurement organization volume with CMS performance evaluations”
  35. Transforming transplantation access: A federal directive for comprehensive pre-waitlisting data collection
  36. Outcomes for Patients With a Deceased Donor Kidney Offer in the New Allocation System
  37. Patient and Provider Attitudes Toward Patient-Facing Kidney Organ Offer Reporting
  38. Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial
  39. Health policy challenges and opportunities for equitable access for transplantation
  40. Post–Kidney Transplant Hospitalizations and Long-Term Outcomes
  41. Out-of-sequence placement of deceased donor kidneys is exacerbating inequities in the United States
  42. Influence of Individual- and Area-Level Social Determinants of Health on Likelihood of Living Versus Deceased Donor Kidney Transplantation
  43. Nonstandard coding of deceased-donor kidney out-of-sequence allocation leads to underrecognition of allocation deviations
  44. Crossing national borders for transplantation: A focused evaluation of deceased donor lung exports from the United States
  45. Associations Among Circle-Based Kidney Allocation, Center Waiting Time, and Likelihood of Deceased-Donor Kidney Transplantation
  46. Equity and the operational considerations of the kidney transplant allocation system
  47. Utilization of transitional care management services and 30-day readmission
  48. Effect of working length determination methods on postoperative pain after root canal treatment: a systematic review and meta-analysis
  49. Practical Considerations for Sharing Race-Based Genetic Research Findings
  50. Reducing Disparities in Access to Kidney Transplantation Regional Study
  51. Allocation biopsies of deceased donor kidneys: a necessary tool to expand the donor pool
  52. Kidney function assessment using cystatin C and serum creatinine in heart transplantation recipients: Implications for valganciclovir dosing
  53. Increasing Incidence of Out-of-Sequence Allocation of Deceased Donor Kidneys
  54. Association Between Split Function of the Retained Kidney and Early Changes in Kidney Function After Living Kidney Donation
  55. Variation Across Organ Procurement Organizations in Deceased‐Donor Kidney Offer Notification Practices
  56. Incomplete reporting of clinically significant acute rejection episodes in the national kidney transplant registry
  57. Donor Estimated Glomerular Filtration Rate With or Without Body Surface Area Indexing and Kidney Transplant Graft Survival
  58. Knowledge, Attitudes, and Beliefs Toward Organ Donation Registration Among Asian Americans: Development and Pilot-testing of Educational Intervention Video
  59. Outcomes of Second Opinions after Adverse Determination of Kidney Transplant Evaluation
  60. Kidney Transplant in Children: Strategic Timing During Summer School Breaks
  61. Are the Centers for Medicare & Medicaid Services metrics evaluating organ procurement organization performance too fragile?
  62. Bridging the Gap in Genomic Implementation: Identifying User Needs for Precision Nephrology
  63. Disparities in Access to Timely Waitlisting Among Pediatric Kidney Transplant Candidates
  64. Highly Sensitized Kidney Transplant Outcomes After the 2014 Kidney Allocation System Change
  65. Acute Kidney Injury Requiring Dialysis After Pediatric Heart Transplant
  66. Kidney Transplant Outcomes From Deceased Donors Who Received Dialysis
  67. Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients
  68. Outcomes of ultra‐low contrast percutaneous coronary intervention in patients with advanced chronic kidney disease
  69. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation
  70. Four Cases of Kidney Transplants With Donor HCV-Derived Immune Complex Glomerulonephritis
  71. Genetic versus self-reported African ancestry of the recipient and neighborhood predictors of kidney transplantation outcomes in 2 multiethnic urban cohorts
  72. Impact of peri-operative red blood cell transfusions for treatment of anemia on acute rejection in renal transplant recipients
  73. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials
  74. Systematic Review of Kidney Injury Biomarkers for the Evaluation of CKD of Uncertain Etiology
  75. Legislative and Regulatory Changes Affecting the US Transplant System
  76. Patient-Centered Quality Measures for Dialysis Care: A Report of a Kidney Disease Outcomes Quality Initiative (KDOQI) Scientific Workshop Sponsored by the National Kidney Foundation
  77. Use of Offer Bypass Filters under the Circular Kidney Allocation System
  78. Cold Ischemia Time and Delayed Graft Function in Kidney Transplantation: A Paired Kidney Analysis
  79. Geospatial Modeling Methods in Epidemiological Kidney Research: An Overview and Practical Example
  80. Calibration of Priority Points for Sensitization Status of Kidney Transplant Candidates in the United States
  81. Association of Implantation Biopsy Findings in Living Donor Kidneys With Donor and Recipient Outcomes
  82. Understanding Delayed Graft Function to Improve Organ Utilization and Patient Outcomes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
  83. Quantifying the Effect of Consent for High–Kidney Donor Profile Index Deceased Donor Transplants in the United States
  84. Should Transplant Nephrology Pursue Recognition from the Accreditation Council for Graduate Medical Education (ACGME)?
  85. Augmenting the United States transplant registry with external mortality data: A moving target ripe for further improvement
  86. Allocation and Utilization Patterns of Deceased Donor Kidneys for Preemptive Transplantation in the United States
  87. Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers
  88. Association between donor kidney cysts and donor and recipient outcomes after living donor kidney transplantation
  89. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study
  90. International Variability in the Epidemiology, Management, and Outcomes of CKD and ESKD: A Systematic Review
  91. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
  92. Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease
  93. Radical Transparency to Improve Equity in the Kidney Allocation System
  94. Kidney Function Assessment Using Cystatin C and Serum Creatinine in Heart Transplantation Recipients: Implications for Valganciclovir Dosing
  95. Differential in Kidney Graft Years on the Basis of Solitary Kidney, Simultaneous Liver–Kidney, and Kidney-after-Liver Transplants
  96. Deceased donor kidneys from higher distressed communities are significantly less likely to be utilized for transplantation
  97. Disparities in Kidney Transplant Waitlisting Among Young Patients Without Medical Comorbidities
  98. The Difference Between Cystatin C– and Creatinine-Based Estimated GFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF
  99. Population Characteristics and Organ Procurement Organization Performance Metrics
  100. UNOS Decisions Impact Data Integrity of the OPTN Data Registry
  101. Strong protective effect of theAPOL1p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease
  102. Discrepant Outcomes between National Kidney Transplant Data Registries in the United States
  103. Increased volume of organ offers and decreased efficiency of kidney placement under circle-based kidney allocation
  104. Why the National Academies Got it Wrong about Changing Preemptive Listing Priority for Kidney Transplantation
  105. Optimal Care for Kidney Health: Development of a Merit-based Incentive Payment System (MIPS) Value Pathway
  106. An experiment on the impact of predictive analytics on kidney offers acceptance decisions
  107. Stakeholders’ perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients’ consensus conference
  108. Natural Antibodies Are Associated With Rejection and Long-term Renal Allograft Loss in a Multicenter International Cohort
  109. Characterization of Transplant Center Decisions to Allocate Kidneys to Candidates With Lower Waiting List Priority
  110. A functional group–guided approach to aptamers for small molecules
  111. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network
  112. Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review
  113. Creation of a Single Institutional Review Board for Collaborative Research in Nephrology: The APOLLO Experience
  114. Increasing Discards as an Unintended Consequence of Recent Changes in United States Kidney Allocation Policy
  115. A metadata framework for computational phenotypes
  116. Untargeted metabolomics of perfusate and their association with hypothermic machine perfusion and allograft failure
  117. Current opinions on DGF management practices: A survey of the United States and Canada
  118. A survey of solid organ transplant recipient attitudes and concerns regarding contraception and pregnancy
  119. Contribution of Estimates of Glomerular Filtration to the Extensive Disparities in Preemptive Listing for Kidney Transplant
  120. Current landscape of kidney allocation: Organ procurement organization perspectives
  121. Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort
  122. Obesity and kidney transplantation
  123. Kidney Transplant Practice in Pandemic Times
  124. Effects of Delayed Graft Function on Transplant Outcomes: A Meta-analysis
  125. Timed Creatinine Clearance and Measured Glomerular Filtration Rate in Living Kidney Donors
  126. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients
  127. Influence of organ quality on the observed association between deceased donor kidney procurement biopsy findings and graft survival
  128. Referral and Evaluation for Kidney Transplantation Following Implementation of the 2014 National Kidney Allocation System
  129. Early Impact of the Circular Model of Kidney Allocation in the United States
  130. Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease
  131. Author Correction: Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions
  132. A Population Health Approach to Transplant Access: Challenging the Status Quo
  133. A tool for decision-making in kidney transplant candidates with poor prognosis to receive deceased donor transplantation in the United States
  134. Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions
  135. Kidney nonprocurement in deceased donors with acute kidney injury
  136. Improving the Utilization of Deceased Donor Kidneys by Prioritizing Patient Preferences
  137. Data carve out in the midst of the COVID ‐19 pandemic
  138. The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
  139. Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers
  140. Association of transplant center market concentration and local organ availability with deceased donor kidney utilization
  141. The role of bypass filters in deceased donor kidney allocation in the United States
  142. Access to kidney transplantation among pediatric candidates with prior solid organ transplants in the United States
  143. Retrospective analysis of the impact of severe obesity on kidney transplant outcomes
  144. Deceased donor kidneys allocated out of sequence by organ procurement organizations
  145. Differences between race-based and race-free estimated glomerular filtration rate among living kidney donors
  146. Clinical Events and Renal Function in the First Year Predict Long-Term Kidney Transplant Survival
  147. Previous SARS-CoV-2 infection or a third dose of vaccine elicited cross-variant neutralizing antibodies in vaccinated solid organ transplant recipients
  148. Evolving Metrics of Quality for Kidney Transplant Candidates: Transplant Center Variability in Delisting and 1-Year Mortality
  149. Challenged comparison of tacrolimus assays
  150. Reproducibility of Chronic Changes on High-Quality Deceased Donor Kidney Allograft Biopsies
  151. Snapshots of nascent RNA reveal cell- and stimulus-specific responses to acute kidney injury
  152. Keys to Driving Implementation of the New Kidney Care Models
  153. Non calcium phosphate binders - Is there any evidence of benefit
  154. Clinically adjudicated deceased donor acute kidney injury and graft outcomes
  155. Trends in the procurement and discard of kidneys from deceased donors with acute kidney injury
  156. Impact of Extending Eligibility for Reinstatement of Waiting Time After Early Allograft Failure: A Decision Analysis
  157. Variations in Deceased Donor Terminal Creatinine Values Reported in the OPTN Data Registry
  158. Underscoring the Case for Better Markers of Kidney Injury in Deceased Donors
  159. Donor‐derived cell‐free DNA and renal allograft rejection in surveillance biopsies and indication biopsies
  160. Employment status at transplant influences ethnic disparities in outcomes after deceased donor kidney transplantation
  161. Previous SARS‐CoV ‐2 infection or a third dose of vaccine elicited cross‐variant neutralising antibodies in vaccinated solid‐organ transplant recipients
  162. Accelerating deceased donor kidney utilization requires more than accelerating placement
  163. Six Years of KI Reports: Milestones Behind and Ahead
  164. Racial disparities in living donor kidney transplantation in the United States
  165. Elevated Neutrophil Gelatinase-Associated Lipocalin Is Associated With the Severity of Kidney Injury and Poor Prognosis of Patients With COVID-19
  166. Declined Offers for Deceased Donor Kidneys Are Not an Independent Reflection of Organ Quality
  167. Diabetic ketoacidosis and mortality in COVID-19 infection
  168. Number of Donor Renal Arteries and Early Outcomes after Deceased Donor Kidney Transplantation
  169. Impact of education on APOL1 testing attitudes among prospective living kidney donors
  170. Febrile neutropenia after kidney transplantation
  171. Value-Based Kidney Care
  172. Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology
  173. COVID-19–Associated Mortality among Kidney Transplant Recipients and Candidates in the United States
  174. Role of deceased donor kidney procurement biopsies in organ allocation
  175. Factors Influencing Ethnic Disparities in Outcomes after Deceased Donor Kidney Transplantation
  176. Impact of Intraoperative Data on Risk Prediction for Mortality After Intra-Abdominal Surgery
  177. A Roadmap for Innovation to Advance Transplant Access and Outcomes: A Position Statement From the National Kidney Foundation
  178. Deceased Donor Kidneys Utilization and Discard Rates During COVID-19 Pandemic in the United States
  179. The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes
  180. Trends and impact on cold ischemia time and clinical outcomes using virtual crossmatch for deceased donor kidney transplantation in the United States
  181. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients
  182. Post-transplant Diabetes Mellitus in Kidney Transplant Recipients: A Multicenter Study
  183. Variations in deceased donor kidney procurement biopsy practice patterns: A survey of U.S. organ procurement organizations
  184. COVID-19 mortality among kidney transplant candidates is strongly associated with social determinants of health
  185. Increased Mortality Associated with Hypermagnesemia in Severe COVID-19 Illness
  186. Protocol for Local On-Site Dialysate Production for Continuous Renal Replacement Therapy during the COVID-19 Pandemic
  187. Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG antibodies in COVID-19–recovered patients who received a kidney transplant
  188. Insulin Sensitivity After Living Donor Nephrectomy
  189. Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City
  190. Patients with High Priority for Kidney Transplant Who Are Not Given Expedited Placement on the Transplant Waiting List Represent Lost Opportunities
  191. Urine Test Predicts Kidney Injury and Death in COVID-19
  192. Healthcare students support opt-out organ donation for practical and moral reasons
  193. Association between procurement biopsy findings and deceased donor kidney outcomes: a paired kidney analysis
  194. A deeper dive into the impact of multiple-organ transplant policy on kidney transplant candidate prognoses
  195. Greater complexity and monitoring of the new Kidney Allocation System: Implications and unintended consequences of concentric circle kidney allocation on network complexity
  196. Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection
  197. The Case | Euglycemic ketoacidosis in a patient on continuous renal replacement therapy
  198. Five Years (and Counting) of Expanding Access to Kidney Disease Research
  199. Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis
  200. Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients
  201. Outcomes of COVID‐19 in solid organ transplant recipients: A matched cohort study
  202. Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United States
  203. Defining a minimal clinically meaningful difference in 12‐month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation
  204. Procurement Biopsy Data Quality Limits Comparability of United States and French Deceased Donor Kidney Biopsies
  205. Association Between Donor-Recipient Biological Relationship and Allograft Outcomes After Living Donor Kidney Transplant
  206. Medical records-based chronic kidney disease phenotype for clinical care and “big data” observational and genetic studies
  207. Left‐digit bias and deceased donor kidney utilization
  208. Factors that Influence Organ Donor Registration Among Asian American Physicians in Queens, New York
  209. Post-acute COVID-19 syndrome
  210. Continuous renal replacement therapy and the COVID pandemic
  211. Development and validation of prediction models for mechanical ventilation, renal replacement therapy, and readmission in COVID-19 patients
  212. Managing Patients with Failing Kidney Allograft
  213. Deceased-Donor Acute Kidney Injury and BK Polyomavirus in Kidney Transplant Recipients
  214. Racial disparities in preemptive waitlisting and deceased donor kidney transplantation: Ethics and solutions
  215. Failure to Advance Access to Kidney Transplantation over Two Decades in the United States
  216. COVID‐19 infection in former living kidney donors
  217. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV‐Viremic Donors
  218. Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation
  219. SARS‐CoV‐2 infection increases tacrolimus concentrations in solid‐organ transplant recipients
  220. Kidney transplant program waitlisting rate as a metric to assess transplant access
  221. Challenges of Clinical Research Administration During the COVID-19 Pandemic
  222. Diabetic Ketoacidosis and Mortality in COVID-19 Infection
  223. Reflections and Next Stages for Kidney International Reports
  224. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy
  225. C4 article: Implications of COVID‐19 in transplantation
  226. Publisher Correction: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  227. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study
  228. Trends in Transplantation Center Use of Kidneys From Deceased Donors With Positive Hepatitis C Virus Nucleic Acid Testing
  229. A Newly Recognized Endemic Region of CKD of Undetermined Etiology (CKDu) in South India—“Tondaimandalam Nephropathy”
  230. Impact of Deceased Donor Kidney Procurement Biopsy Technique on Histologic Accuracy
  231. Rule Out Acute Kidney Injury in the Emergency Department With a Urinary Dipstick
  232. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  233. Major Variation across Local Transplant Centers in Probability of Kidney Transplant for Wait-Listed Patients
  234. Telehealth in outpatient management of kidney transplant recipients during COVID‐19 pandemic in New York
  235. Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study
  236. Reversal of Donor Hepatitis C Virus–Related Mesangial Proliferative GN in a Kidney Transplant Recipient
  237. Effect of the ASCENT Intervention to Increase Knowledge of Kidney Allocation Policy Changes Among Dialysis Providers
  238. Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series
  239. Re: COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter
  240. Financial impact of delayed graft function in kidney transplantation
  241. Intraoperative Data Enhance the Detection of High-Risk Acute Kidney Injury Patients When Added to a Baseline Prediction Model
  242. Impact of warm ischemia time on outcomes for kidneys donated after cardiac death Post‐KAS
  243. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis
  244. Content Coverage Evaluation of the OMOP Vocabulary on the Transplant Domain Focusing on Concepts Relevant for Kidney Transplant Outcomes Analysis
  245. Dashboards to Facilitate Nephrology Disaster Planning in the COVID-19 Era
  246. Uromodulin to Osteopontin Ratio in Deceased Donor Urine Is Associated With Kidney Graft Outcomes
  247. Treatment of borderline infiltrates with minimal inflammation in kidney transplant recipients has no effect on allograft or patient outcomes
  248. Center-related Bias in MELD Scores Within a Liver Transplant UNOS Region: A Call for Standardization
  249. Extrapulmonary manifestations of COVID-19
  250. Nephrology Disaster Response in NYC
  251. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease
  252. Urine Injury Biomarkers Are Not Associated With Kidney Transplant Failure
  253. Presentation and Outcomes of Patients with ESKD and COVID-19
  254. Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019
  255. Early Kidney Allograft Failure After Simultaneous Liver-kidney Transplantation: Evidence for Utilization of the Safety Net?
  256. Kidney non‐procurement in solid organ donors in the United States
  257. COVID‐19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter
  258. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York
  259. Pilot Study of Return of Genetic Results to Patients in Adult Nephrology
  260. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale
  261. Using race in the estimation of glomerular filtration rates
  262. Kidney International Reports: Three Years of Publication
  263. Reproducibility of Deceased Donor Kidney Procurement Biopsies
  264. Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study
  265. Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device
  266. Utilization of Hepatitis C Virus (HCV)‐Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?
  267. Variation of ApoL1 Testing Practices for Living Kidney Donors
  268. Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant
  269. Geographic Variation in the Availability of Deceased Donor Kidneys per Wait-Listed Candidate in the United States
  270. Evaluation of kidney allocation critical data validity in the OPTN registry using dialysis dates
  271. A Donor Utilization Index to Assess the Utilization and Discard of Deceased Donor Kidneys Perceived as High Risk
  272. Trends in Disparities in Preemptive Kidney Transplantation in the United States
  273. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys
  274. Regional Disparities in Transplantation With Deceased Donor Kidneys With Kidney Donor Profile Index Less Than 20% Among Candidates With Top 20% Estimated Post Transplant Survival
  275. Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates
  276. The authors reply
  277. Ultra-low-contrast angiography in patients with advanced chronic kidney disease and previous coronary artery bypass surgery
  278. Patient-Centered Outcomes with Second Kidney Transplant
  279. A Focus on APOL1 and Kidney Disease
  280. Cultural barriers to organ donation among Chinese and Korean individuals in the United States: a systematic review
  281. Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection
  282. Health-related quality of life in glomerular disease
  283. Deceased Donor Kidneys Are Harder to Place on the Weekend
  284. APOL1 Genetic Testing in Living Kidney Transplant Donors
  285. Quality Metrics in Kidney Transplantation: Current Landscape, Trials and Tribulations, Lessons Learned, and a Call for Reform
  286. Outcomes of kidney transplant from deceased donors with acute kidney injury and prolonged cold ischemia time - a retrospective cohort study
  287. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants
  288. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease
  289. Diagnostic Utility of Exome Sequencing for Kidney Disease
  290. Deceased-donor acute kidney injury is not associated with kidney allograft failure
  291. KI Reports in 2019: Further Expanding Access to Research in Nephrology
  292. Donor’s APOL1 Risk Genotype and “Second Hits” Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases
  293. Using technology to enhance medication regimen education after solid organ transplantation
  294. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts
  295. Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study
  296. Outcomes for potential kidney transplant recipients offered public health service increased risk kidneys: A single-center experience
  297. Deceased brain dead donor liver transplantation and utilization in the United States
  298. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study
  299. Association between the “Timed Up and Go Test” at transplant evaluation and outcomes after kidney transplantation
  300. Procurement Biopsies in the Evaluation of Deceased Donor Kidneys
  301. Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards
  302. Current opinions in organ allocation
  303. Kidney transplant offers to deceased candidates
  304. Patients prioritize waitlist over posttransplant outcomes when evaluating kidney transplant centers
  305. Factors leading to the discard of deceased donor kidneys in the United States
  306. Expanding transplant outcomes research opportunities through the use of a common data model
  307. Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes
  308. Induction regimen and survival in simultaneous heart-kidney transplant recipients
  309. Kidney International Reports : Two Years of Publication
  310. Racial/ethnic disparities in waitlisting for deceased donor kidney transplantation 1 year after implementation of the new national kidney allocation system
  311. Awareness of Racial Disparities in Kidney Transplantation among Health Care Providers in Dialysis Facilities
  312. Effect of the iChoose Kidney decision aid in improving knowledge about treatment options among transplant candidates: A randomized controlled trial
  313. Standardized Transplantation Referral Ratio to Assess Performance of Transplant Referral among Dialysis Facilities
  314. Awareness of the New Kidney Allocation System among United States Dialysis Providers with Low Waitlisting
  315. Emergency department use among kidney transplant recipients in the United States
  316. Characteristics and Performance of Unilateral Kidney Transplants from Deceased Donors
  317. Relation of Coronary Flow Reserve to Other Findings on Positron Emission Tomography Myocardial Perfusion Imaging and Left Heart Catheterization in Patients With End-stage Renal Disease Being Evaluated for Kidney Transplant
  318. Achieving Equity through Reducing Variability in Accepting Deceased Donor Kidney Offers
  319. Association between Reperfusion Renal Allograft Biopsy Findings and Transplant Outcomes
  320. Kidney International Reports : The First Year
  321. Predictive Value of Using Initial Versus Terminal Deceased Donor Creatinine to Calculate the Kidney Donor Risk Index
  322. Acute Kidney Injury Recognition in Low- and Middle-Income Countries
  323. New Kidney Allocation System Associated With Increased Rates Of Transplants Among Black And Hispanic Patients
  324. Decisional conflict between treatment options among end-stage renal disease patients evaluated for kidney transplantation
  325. The Reply
  326. United States Dialysis Facilities With a Racial Disparity in Kidney Transplant Waitlisting
  327. Coronary Plaque Characteristics in Hemodialysis-Dependent Patients as Assessed by Optical Coherence Tomography
  328. The ASCENT (Allocation System Changes for Equity in Kidney Transplantation) Study: A Randomized Effectiveness-Implementation Study to Improve Kidney Transplant Waitlisting and Reduce Racial Disparity
  329. KI Reports and World Kidney Day
  330. Sense and sensitivity: incompatible patients and their donors in kidney transplantation
  331. Combined Percutaneous Transrenal and Transfemoral Endovascular Recanalization and Angioplastic Reconstruction of a Disrupted Transplant Renal Artery Stent: A Novel Salvage Technique
  332. Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index
  333. Association of Weight Perception, Race and Readiness to Quit Smoking amongst a Cohort of Workers
  334. Incidence of Hyponatremia with High-Dose Trimethoprim-Sulfamethoxazole Exposure
  335. Simultaneous Liver-Kidney Transplantation in Liver Transplant Candidates With Renal Dysfunction: Importance of Creatinine Levels, Dialysis, and Organ Quality in Survival
  336. Emergency Department Use and Hospital Admissions Among Patients With End-Stage Renal Disease in the United States
  337. Diagnosis and Management of Cardiovascular Disease in Advanced and End‐Stage Renal Disease
  338. The weekend effect alters the procurement and discard rates of deceased donor kidneys in the United States
  339. Rejection and graft outcomes based on induction agents in deceased donort transplantation
  340. A Randomized Controlled Trial of a Mobile Clinical Decision Aid to Improve Access to Kidney Transplantation: iChoose Kidney
  341. iChoose Kidney
  342. Applications for Detection of Acute Kidney Injury Using Electronic Medical Records and Clinical Information Systems: Workgroup Statements from the 15th ADQI Consensus Conference
  343. Pre-ESRD Care and Mortality in Incident ESRD Patients With Multiple Myeloma
  344. APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors
  345. Electrolyte and Acid–Base Disturbances in Diabetes Mellitus
  346. One Size Does Not Fit All—Regional Variation in the Impact of the Share 35 Liver Allocation Policy
  347. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity
  348. The Authors Reply
  349. Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated With Renal Allograft Failure
  350. Racial and ethnic disparities in pediatric renal allograft survival in the United States
  351. Integrating Real Time Data to Improve Outcomes in Acute Kidney Injury
  352. α–Intercalated cells defend the urinary system from bacterial infection
  353. Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case-controlled study
  354. Kidney Transplantation and the Intensity of Poverty in the Contiguous United States
  355. The Authors’ Reply
  356. α–Intercalated cells defend the urinary system from bacterial infection
  357. Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology
  358. Kidneys at Higher Risk of Discard: Expanding the Role of Dual Kidney Transplantation
  359. Recovery of Renal Function among ESRD Patients in the US Medicare Program
  360. Prevalence of Hyponatremia and Association with Mortality: Results from NHANES
  361. Trimethoprim-Associated Hyponatremia
  362. Preformed Donor-Specific Antibodies and Risk of Antibody-Mediated Rejection in Repeat Renal Transplantation
  363. Risk factors associated withClostridium difficileinfection after kidney and pancreas transplantation
  364. Future of Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the United States
  365. The changing pattern of glomerular disease in HIV and Hepatitis C co-infected patients in the era of HAART
  366. Pancreas–kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes
  367. Risk of Malignancy After Renal Transplantation
  368. Donor-Specific Antibodies Adversely Affect Kidney Allograft Outcomes
  369. Toxicokinetics of metformin-associated lactic acidosis with continuous renal replacement therapy
  370. Impact of Small Variations in the Delivered Dose of Rabbit Antithymocyte Induction Therapy in Kidney Transplantation With Early Corticosteroid Withdrawal
  371. Availability, Utilization and Outcomes of Deceased Diabetic Donor Kidneys; Analysis Based on the UNOS Registry
  372. Cost-effectiveness of Treating Chronic Anemia with Epoetin Alfa among Hemodialysis Patients in the United States
  373. Identifying Hemodialysis Catheter Recirculation Using Effective Ionic Dialysance
  374. Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy
  375. Reduced Fracture Risk With Early Corticosteroid Withdrawal After Kidney Transplant
  376. Achieving the goal
  377. Early Improvement in Albuminuria in Non-diabetic Patients after Roux-en-Y Bariatric Surgery
  378. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy
  379. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy
  380. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities
  381. Do meta-analyses in nephrology change the way we treat patients?
  382. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
  383. Effective Ionic Dialysance/Blood Flow Rate Ratio: An Indicator of Access Recirculation in Arteriovenous Fistulae
  384. 197: Renal Prognosis in HIV HCV Co-Infected Patients in the HAART ERA
  385. The Case ∣ 41-year-old HIV patient with proteinuria and progressive renal dysfunction
  386. Acute bilateral renal infarction secondary to cocaine-induced vasospasm
  387. Influence of concomitant prednisolone on trimethoprim-associated hyperkalaemia
  388. In Reply
  389. Hypokalemia During Sickle Cell Crises Apparently Due to Intermittent Mineralocorticoid Excess
  390. Proteinuria lowers the risk of amphotericin B-associated hypokalaemia
  391. 100
  392. SLEEP DISORDERS IN PATIENTS ON CHRONIC HEMODIALYSIS IN CENTRAL HARLEM
  393. Chyluria presenting as milky urine and nephrotic-range proteinuria
  394. A case of AIDS associated cryptococcal meningitis with multiple cranial nerve neuropathies
  395. Unusual Biopsy Findings in a Hepatitis C–Infected White Man With Cryoglobulinemia, Purpuric Rash, and Renal Failure
  396. Pneumocystosis Diagnosed by Bronchoalveolar Lavage in an Immunocompetent Polysubstance Abuser